Development of mTORC1 specific agents for evaluation of HER2 targeted therapy using PET

被引：0
|
作者：
Wichmann, Christian W. [1 ,2 ]
Ackermann, Uwe [2 ,3 ]
Parslow, Adam C. [3 ,4 ]
Rigopoulos, Angela [3 ]
Scott, Andrew M. [3 ,4 ]
White, Jonathan M. [1 ]
机构：
[1] Univ Melbourne, Sch Chem, Bio21 Inst, Parkville, Vic, Australia
[2] Austin Hlth, Ctr PET, Heidelberg, Vic, Australia
[3] Olivia Newton John Canc Res Inst, Tumour Targeting Lab, Heidelberg, Vic, Australia
[4] La Trobe Univ, Sch Canc Med, Bundoora, Vic, Australia
来源：
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2017年 / 60卷
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
P 333
引用
收藏
页码：S506 / S506
页数：1
相关论文
共 50 条
  • [41] mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
    Yang, Jin Young
    Madrakhimov, Sanjar Batirovich
    Ahn, Dong Hyuck
    Chang, Hun Soo
    Jung, Sang Joon
    Nah, Seung Kwan
    Park, Ha Yan
    Park, Tae Kwann
    CELL COMMUNICATION AND SIGNALING, 2019, 17 (1)
  • [42] mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
    Park, Tae Kwann
    Yang, Jin Young
    Madrakhimov, Sanjar
    Ohn, Young-Hoon
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [43] Notch signaling regulates recurrence in a model of HER2 targeted therapy
    Abravanel, Daniel L.
    Sterner, Christopher J.
    Pan, Tien-chi
    Belka, George K.
    Chodosh, Lewis A.
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [44] Identification of biomarkers of resistance to HER2 targeted therapy using loss of function genetic screens
    Bernards, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S3 - S3
  • [45] mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
    Jin Young Yang
    Sanjar Batirovich Madrakhimov
    Dong Hyuck Ahn
    Hun Soo Chang
    Sang Joon Jung
    Seung Kwan Nah
    Ha Yan Park
    Tae Kwann Park
    Cell Communication and Signaling, 17
  • [46] HER2 targeted therapy in breast cancer...beyond Herceptin
    Sumanta Kumar Pal
    Mark Pegram
    Reviews in Endocrine and Metabolic Disorders, 2007, 8 : 269 - 277
  • [47] HER2 targeted therapy in breast cancer...beyond Herceptin
    Pal, Sumanta Kumar
    Pegram, Mark
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2007, 8 (03): : 269 - 277
  • [48] Alternative targeted therapy for early Her2 positive breast cancer
    Harvey, Sandra L.
    Khasraw, Mustafa
    GLAND SURGERY, 2013, 2 (01) : 42 - 45
  • [49] Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene
    Harbeck, Nadia
    Pegram, Mark D.
    Rueschoff, Josef
    Moebus, Volker
    BREAST CARE, 2010, 5 : 3 - 7
  • [50] MIRNA signatures as predictors of resistance to endocrine and HER2 targeted therapy
    Healy, N. A.
    Schiff, R.
    Osborne, C. K.
    Miller, N.
    Kerin, M. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : S264 - S264
12345